Home Cart 0 Sign in  
X

[ CAS No. 56700-70-0 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 56700-70-0
Chemical Structure| 56700-70-0
Chemical Structure| 56700-70-0
Structure of 56700-70-0 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 56700-70-0 ]

Related Doc. of [ 56700-70-0 ]

Alternatived Products of [ 56700-70-0 ]

Product Details of [ 56700-70-0 ]

CAS No. :56700-70-0 MDL No. :MFCD02179231
Formula : C10H14N2O2 Boiling Point : -
Linear Structure Formula :- InChI Key :WKHGDPZRLXDVMJ-UHFFFAOYSA-N
M.W :194.23 Pubchem ID :10932321
Synonyms :

Calculated chemistry of [ 56700-70-0 ]

Physicochemical Properties

Num. heavy atoms : 14
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.4
Num. rotatable bonds : 4
Num. H-bond acceptors : 3.0
Num. H-bond donors : 1.0
Molar Refractivity : 54.48
TPSA : 51.22 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.21 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.1
Log Po/w (XLOGP3) : 1.8
Log Po/w (WLOGP) : 2.24
Log Po/w (MLOGP) : 0.84
Log Po/w (SILICOS-IT) : 1.12
Consensus Log Po/w : 1.62

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.23
Solubility : 1.14 mg/ml ; 0.00587 mol/l
Class : Soluble
Log S (Ali) : -2.49
Solubility : 0.622 mg/ml ; 0.0032 mol/l
Class : Soluble
Log S (SILICOS-IT) : -2.98
Solubility : 0.204 mg/ml ; 0.00105 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.24

Safety of [ 56700-70-0 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P280 UN#:N/A
Hazard Statements:H302-H317 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 56700-70-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 56700-70-0 ]
  • Downstream synthetic route of [ 56700-70-0 ]

[ 56700-70-0 ] Synthesis Path-Upstream   1~20

  • 1
  • [ 56700-70-0 ]
  • [ 271-29-4 ]
Reference: [1] Synthesis, 1996, # 7, p. 877 - 882
  • 2
  • [ 56700-70-0 ]
  • [ 273-75-6 ]
Reference: [1] Heterocycles, 2004, vol. 63, # 7, p. 1555 - 1561
[2] Patent: WO2014/190199, 2014, A1,
  • 3
  • [ 56700-70-0 ]
  • [ 7579-20-6 ]
Reference: [1] Patent: WO2008/130021, 2008, A2,
  • 4
  • [ 56700-70-0 ]
  • [ 55279-30-6 ]
Reference: [1] Patent: WO2008/130021, 2008, A2,
  • 5
  • [ 59-67-6 ]
  • [ 75-65-0 ]
  • [ 56700-70-0 ]
Reference: [1] Patent: EP2274983, 2011, A1, . Location in patent: Page/Page column 127-128
[2] Patent: US2011/39843, 2011, A1, . Location in patent: Page/Page column 80-81
[3] Patent: WO2011/40629, 2011, A1, . Location in patent: Page/Page column 212
[4] Patent: WO2011/49220, 2011, A1, . Location in patent: Page/Page column 211
[5] Patent: WO2011/49221, 2011, A1, . Location in patent: Page/Page column 212-213
[6] Patent: WO2011/49223, 2011, A1, . Location in patent: Page/Page column 211
[7] Patent: WO2011/49222, 2011, A1, . Location in patent: Page/Page column 215-216
  • 6
  • [ 24424-99-5 ]
  • [ 56700-70-0 ]
YieldReaction ConditionsOperation in experiment
67%
Stage #1: With sodium hexamethyldisilazane In tetrahydrofuran for 0.25 h;
Stage #2: for 15 h;
3-Aminopyridine (4.29 g, 45.. 6 mmol) was dissolved in THF (100 mL). A 1 M THF solution of sodium hexamethyl-disilazide (NaHMDS, 100 mL, 100 mmol) was added dropwise via an addition funnel. After 15 min, a solution of di-t-butyl dicarbonate[ (Boc) 201 (11.92 g, 54.6 mmol) in THF (100 mL) was added dropwise. After 15 min, the reaction was quenched with water (100 mL) and extracted with EtOAc (500 mL). The organic layer was washed with water (2 x 100 mL). The aqueous layers were combined and extracted with EtOAc (200 mL). The organic layers were combined, dried over sodium sulfate, filtered, and concentrated. The crude material was purified by flash column chromatography (30percentEtoAc/CH2C12) to give the desired product (5.195 g, 30.5 mmol, 67percent) as an orange solid. 1NMR (400 MHz,DMSO-d6) 9.53 (s,1H) ; 8. 57 (s, 1H) ; 8. 14 (d, J=4.4 Hz, 1H) ; 7.84 (d, J=8.0 Hz, 1H) ; 7.25 (m, 1H) ; 1.44 (s, 9H). <Desc/Clms Page number 37>IS-MS, m/e 195.3(m+1). Analysis forCl0H14N2 2 :Calcd: C, 61.84 ; H, 7.27 ; N, 14.42 ;Found: C, 61.94 ; H, 7.18 ; N,14. 38.
Reference: [1] Patent: WO2005/49604, 2005, A2, . Location in patent: Page/Page column 36-37
  • 7
  • [ 462-08-8 ]
  • [ 24424-99-5 ]
  • [ 56700-70-0 ]
YieldReaction ConditionsOperation in experiment
85%
Stage #1: With sodium hexamethyldisilazane In tetrahydrofuran for 0.5 h;
Stage #2: for 3 h;
To a solution of pyridin-3 -amine (2.5 g, 26.3 mmol) in anhydrous tetrahydiOfuran (80 mL) was added 1 M sodium bis(trimethylsilyl)amide in tetrahydrofuran (52.6 mL, 52.6 mmol) in a steady stream. The mixture was stirred for 30 minutes, treated dropwise with a solution of di-feri-butyl dicarbonate (5.92 g, 26.3 mmol) in anhydrous tetrahydrofuran (20 mL), stirred for 3 hours and concentrated. The residue was dissolved in ethyl acetate, washed with saturated aqueous sodium chloride, dried over anhydrous MgSCu, filtered, and concentrated by rotary evaporation. Purification by chromatography on silica eluting with 3percent> methanol in dichloromethane afforded an amber semisolid. The material was dissolved in ethyl acetate, treated with decolorizing charcoal and vacuum filtered through diatomaceous earth. Concentration of the filtrate by rotary evaporation afforded the title compound as a light gold solid (4.35 g, 85percent). MS (DCI+) m/z 195 (M+H)+.
Reference: [1] Journal of Organic Chemistry, 2018, vol. 83, # 3, p. 1634 - 1642
[2] Patent: WO2012/87833, 2012, A1, . Location in patent: Page/Page column 148
[3] Tetrahedron Letters, 2010, vol. 51, # 21, p. 2797 - 2799
[4] Organic Letters, 2004, vol. 6, # 20, p. 3517 - 3520
[5] Heterocycles, 1999, vol. 51, # 4, p. 721 - 726
[6] Canadian Journal of Chemistry, 1987, vol. 65, # 6, p. 1158 - 1161
[7] Organic Letters, 2004, vol. 6, # 21, p. 3869 - 3871
[8] Tetrahedron Letters, 1994, vol. 35, # 48, p. 9003 - 9006
[9] Bioorganic and Medicinal Chemistry Letters, 2005, vol. 15, # 6, p. 1637 - 1640
[10] Patent: US2003/78277, 2003, A1,
[11] Patent: US2005/159423, 2005, A1, . Location in patent: Page/Page column 18
[12] Patent: EP2269986, 2011, A1, . Location in patent: Page/Page column 17
[13] Patent: WO2012/48129, 2012, A2, . Location in patent: Page/Page column 287
[14] Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, # 22, p. 5580 - 5590
[15] Patent: WO2008/130021, 2008, A2, . Location in patent: Page/Page column 415-416
  • 8
  • [ 626-55-1 ]
  • [ 4248-19-5 ]
  • [ 56700-70-0 ]
Reference: [1] Green Chemistry, 2014, vol. 16, # 3, p. 1480 - 1488
[2] Journal of Organic Chemistry, 2012, vol. 77, # 12, p. 5279 - 5285
[3] Journal of Organic Chemistry, 2009, vol. 74, # 12, p. 4634 - 4637
[4] Tetrahedron Letters, 2010, vol. 51, # 33, p. 4445 - 4448
  • 9
  • [ 462-08-8 ]
  • [ 34619-03-9 ]
  • [ 56700-70-0 ]
Reference: [1] Patent: EP1452525, 2004, A1, . Location in patent: Page 20-21
  • 10
  • [ 22236-96-0 ]
  • [ 75-65-0 ]
  • [ 56700-70-0 ]
Reference: [1] Synthesis, 1982, # 3, p. 225 - 227
  • 11
  • [ 626-60-8 ]
  • [ 4248-19-5 ]
  • [ 56700-70-0 ]
Reference: [1] Tetrahedron Letters, 2010, vol. 51, # 33, p. 4445 - 4448
  • 12
  • [ 98-92-0 ]
  • [ 75-65-0 ]
  • [ 56700-70-0 ]
Reference: [1] Journal of Medicinal Chemistry, 1988, vol. 31, # 11, p. 2136 - 2145
[2] Patent: WO2005/113552, 2005, A1, . Location in patent: Page/Page column 21
  • 13
  • [ 4013-72-3 ]
  • [ 75-65-0 ]
  • [ 39642-60-9 ]
  • [ 56700-70-0 ]
Reference: [1] Journal of Organic Chemistry USSR (English Translation), 1988, vol. 24, # 11, p. 2210 - 2211[2] Zhurnal Organicheskoi Khimii, 1988, vol. 24, # 11, p. 2450 - 2451
  • 14
  • [ 56700-70-0 ]
  • [ 58484-01-8 ]
Reference: [1] Patent: WO2008/130021, 2008, A2,
  • 15
  • [ 2591-86-8 ]
  • [ 56700-70-0 ]
  • [ 116026-95-0 ]
Reference: [1] Journal of Medicinal Chemistry, 1988, vol. 31, # 11, p. 2136 - 2145
  • 16
  • [ 594-19-4 ]
  • [ 56700-70-0 ]
  • [ 116026-95-0 ]
Reference: [1] Patent: US6479512, 2002, B1,
  • 17
  • [ 56700-70-0 ]
  • [ 184637-48-7 ]
Reference: [1] Patent: US2005/159423, 2005, A1, . Location in patent: Page/Page column 18
[2] Patent: EP2269986, 2011, A1, . Location in patent: Page/Page column 17-18
[3] Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, # 22, p. 5580 - 5590
  • 18
  • [ 56700-70-0 ]
  • [ 154048-89-2 ]
YieldReaction ConditionsOperation in experiment
71%
Stage #1: With tert.-butyl lithium In tetrahydrofuran; pentane at -75 - -60℃; Inert atmosphere
Stage #2: With iodine In tetrahydrofuran; pentane at -75 - -63℃;
In heat-dried argon purged 4-neck flask was placed a solution of pyridin-3-yl-carbamic acid tert-butyl ester (10 g, 51.5 mmol, CAS RN 56700-70-0) in THF (100 mL). After cooling down to -75° C., tert-butyllithium (1.7M solution in n-pentane, 66.6 mL, 113 mmol) was added dropwise over 15 min keeping the temperature below -60° C. The resulting light brown suspension was stirred at -75° C. for 3.75 h. A solution of iodine (28.7 g, 113 mmol) in THF (50 mL) was added dropwise over 20 min. below -63° C. The reaction mixture was stirred at -75° C. for 1.5 h and then poured on saturated aqueous NH4Cl solution (1000 mL) and EtOAc (500 mL). The layers were separated. The organic layer was washed once with 10percent aqueous Na2S2O3 solution (300 mL) and once with brine (250 mL), dried over MgSO4, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 120 g column using a MPLC system eluting with a gradient of n-heptane:EtOAc (100:0 to 0:100). Yellow solid (11.7 g; 71percent). MS (ESI): m/z=321.1 [M+H]+.
71%
Stage #1: With tert.-butyl lithium In tetrahydrofuran; pentane at -75 - -60℃; for 3.75 h;
Stage #2: With iodine In tetrahydrofuran; pentane at -75 - -63℃; for 1.5 h;
Stage #3: With ammonium chloride In tetrahydrofuran; water; ethyl acetate; pentane
In heat-dried argon purged 4-neck flask was placed a solution of pyridin-3-yl-carbamic acid tert-butyl ester (10 g, 51.5 mmol, CAS RN 56700-70-0) in THF (100 mL). After cooling down to -75 °C, tert-butyllithium (1.7M solution in n-pentane, 66.6 mL, 113 mmol) was added dropwise over 15 min. keeping the temperature below -60 °C. The resulting light brown suspension was stirred at -75 °C for 3.75 h. A solution of iodine (28.7 g, 113 mmol) in THF (50 niL) was added dropwise over 20 min. below -63 °C. The reaction mixture was stirred at -75 °C for 1.5 h and then poured on saturated aqueous NH4C1 solution (1000 mL) and EtOAc (500 mL). The layers were separated. The organic layer was washed once with 10percent aqueous Na2S203 solution (300 mL) and once with brine (250 mL), dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 120 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Yellow solid (11.7 g; 71percent). MS (ESI): m/z = 321.1 [M+H]+.
65%
Stage #1: With tert.-butyl lithium In tetrahydrofuran at -78 - -30℃; for 2.75 h; Inert atmosphere
Stage #2: With iodine In tetrahydrofuran at -78 - -30℃; for 0.916667 h; Inert atmosphere
Stage #3: With water In tetrahydrofuran at 0℃; Inert atmosphere
A solution of Example 17A (2.16 g, 11.12 mmol) in anhydrous tetrahydrofuran (50 mL) under N2 was cooled to -78 °C and treated dropwise with 1.7 tert-butyl lithium in pentane (16.35 mL, 27.8 mmol). The mixture was stirred at -78 °C for 15 minutes, warmed to -30 °C and stirred for 2.5 hours. The dark brick-red solution was re-cooled to -78 °C and a solution of iodine (7.06 g, 27.8 mmol) in anhydrous tetrahydrofuran (18.5 mL) was added dropwise over 20 minutes to give a thick reaction mixture that was difficult to stir. The mixture was swirled at -78 °C for 15 minutes, warmed to -30°C, stirred for 40 minutes and warmed to 0 °C. The mixture was quenched by addition of H20 (100 mL) and treated with solid Na2SC>3 until a constant yellow color was achieved. The mixture was diluted with ethyl acetate and the layers were separated. The organic layer was washed with saturated sodium chloride solution, dried over anhydrous Na2S04, filtered, and the filtrate was concentrated by rotary evaporation. Purification by chromatography on silica eluting with 10percent-20percent ethyl acetate in dichloromethane afforded the title compound as an amber oil which crystallized upon standing (2.32 g, 65percent). MS (DCI+) m/z 321 (M+H)+.
Reference: [1] Patent: US2012/232051, 2012, A1, . Location in patent: Page/Page column 74
[2] Patent: WO2012/117000, 2012, A1, . Location in patent: Page/Page column 157; 158
[3] Patent: WO2012/87833, 2012, A1, . Location in patent: Page/Page column 148-149
[4] Journal of Organic Chemistry, 2018, vol. 83, # 3, p. 1634 - 1642
[5] Heterocycles, 1999, vol. 51, # 4, p. 721 - 726
[6] Patent: US6281227, 2001, B1,
  • 19
  • [ 109-72-8 ]
  • [ 20485-44-3 ]
  • [ 56700-70-0 ]
  • [ 154048-89-2 ]
Reference: [1] Patent: US2003/78277, 2003, A1,
  • 20
  • [ 56700-70-0 ]
  • [ 883107-62-8 ]
Reference: [1] Patent: WO2008/130021, 2008, A2,
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 56700-70-0 ]

Amides

Chemical Structure| 98400-69-2

[ 98400-69-2 ]

4-(Boc-Amino)pyridine

Similarity: 0.91

Chemical Structure| 323578-38-7

[ 323578-38-7 ]

tert-Butyl (6-(hydroxymethyl)pyridin-3-yl)carbamate

Similarity: 0.88

Chemical Structure| 116026-95-0

[ 116026-95-0 ]

tert-Butyl (4-formylpyridin-3-yl)carbamate

Similarity: 0.86

Chemical Structure| 116026-98-3

[ 116026-98-3 ]

tert-Butyl (2-bromopyridin-3-yl)carbamate

Similarity: 0.85

Chemical Structure| 171178-45-3

[ 171178-45-3 ]

tert-Butyl (6-chloropyridin-3-yl)carbamate

Similarity: 0.85

Amines

Chemical Structure| 98400-69-2

[ 98400-69-2 ]

4-(Boc-Amino)pyridine

Similarity: 0.91

Chemical Structure| 323578-38-7

[ 323578-38-7 ]

tert-Butyl (6-(hydroxymethyl)pyridin-3-yl)carbamate

Similarity: 0.88

Chemical Structure| 116026-95-0

[ 116026-95-0 ]

tert-Butyl (4-formylpyridin-3-yl)carbamate

Similarity: 0.86

Chemical Structure| 116026-98-3

[ 116026-98-3 ]

tert-Butyl (2-bromopyridin-3-yl)carbamate

Similarity: 0.85

Chemical Structure| 171178-45-3

[ 171178-45-3 ]

tert-Butyl (6-chloropyridin-3-yl)carbamate

Similarity: 0.85

Related Parent Nucleus of
[ 56700-70-0 ]

Pyridines

Chemical Structure| 98400-69-2

[ 98400-69-2 ]

4-(Boc-Amino)pyridine

Similarity: 0.91

Chemical Structure| 323578-38-7

[ 323578-38-7 ]

tert-Butyl (6-(hydroxymethyl)pyridin-3-yl)carbamate

Similarity: 0.88

Chemical Structure| 116026-95-0

[ 116026-95-0 ]

tert-Butyl (4-formylpyridin-3-yl)carbamate

Similarity: 0.86

Chemical Structure| 116026-98-3

[ 116026-98-3 ]

tert-Butyl (2-bromopyridin-3-yl)carbamate

Similarity: 0.85

Chemical Structure| 171178-45-3

[ 171178-45-3 ]

tert-Butyl (6-chloropyridin-3-yl)carbamate

Similarity: 0.85